RA Capital Adds $1.4M to Artiva Stake, Continuing Accumulation Streak
ARTV has more than doubled off its 52-week low of $2.22 on light trading volume (0.3× avg).
Summary
RA Capital, a director and 10% owner, bought $1.4M of Artiva Biotherapeutics stock, extending a pattern of significant insider accumulation following positive clinical data.
Key Events · Ownership and Investor Activity · ARTV
-
RA Capital Buys $1.4M in Open Market
RA Capital purchased 160,354 shares at $8.93-$8.95 per share, totaling $1,432,119, on July 16-17, 2026.
-
Fourth Major Purchase in Two Months
This follows $100M, $7.65M, and $4M purchases by RA Capital since May 2026, signaling sustained conviction.
-
Post-Transaction Holdings Reach 16.98M Shares
RA Capital now holds 16,977,927 shares, representing a significant ownership stake in the company.
-
Purchase at Slight Discount to Current Price
The buy was executed at $8.93-$8.95, slightly below the current price of $9.12, indicating continued accumulation near market levels.
Analysis · ARTV · Life Sciences
RA Capital, a major institutional investor with board representation, purchased an additional $1.4 million of Artiva Biotherapeutics stock at $8.93-$8.95 per share. This is the fourth open-market purchase by RA Capital in the past two months, following buys of $100M, $7.65M, and $4M, reinforcing a strong accumulation signal. The purchase comes after positive clinical data for AlloNK and a $300M public offering, suggesting continued conviction in the autoimmune pipeline.
At the time of this filing, ARTV was trading at $9.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $444.6M. The 52-week trading range was $2.22 to $14.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.